Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Summary

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

Timeline

Start

2014-05

Primary completion

2023-01-25

Completion

2027-08

Publications

• Botto B, Boccomini C, Evangelista A, Zilioli VR, Anastasia A, Cavallo F, Merli F, Zanni M, Tani M, Chiarenza A, Liberati AM, Conconi A, Rusconi C, Bari A, Del Giudice I, Gaidano G, Spina M, Maschio N, Castellino C, Rota-Scalabrini D, Puccini B, Arcari A, Bigliardi S, Matta GME, Bianchi B, Mannina D, Marino D, Galieni P, Ciambelli F, Musuraca G, Muzi C, Bottelli C, Genuardi E, Meli E, Ferrero S, Luminari S, Ladetto M, Ciccone G, Vitolo U. Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. Blood Adv. 2026 Jun 25:bloodadvances.2025018732. doi: 10.1182/bloodadvances.2025018732. Online ahead of print.

Drugs

Indications